在接受奎尼丁治疗的患者中，鹰爪豆碱氧化实际上被消除了。
Sparteine oxidation is practically abolished in quinidine-treated patients.
作者信息
Brinn R, Brøsen K, Gram L F, Haghfelt T, Otton S V
出版信息
Br J Clin Pharmacol. 1986 Aug;22(2):194-7. doi: 10.1111/j.1365-2125.1986.tb05250.x.
Abstract
In eight patients a sparteine-test was carried out immediately before and after 1 week of treatment with quinidine 600-800 mg day-1. Before treatment one patient was classified as a poor metaboliser (metabolic ratio: greater than or equal to 20), and seven patients as extensive metabolisers. During quinidine treatment, the formation of sparteine metabolites (2- and 5-dehydrosparteine) was practically abolished. Patients initially classified as extensive metabolisers thus exhibited the phenotype of poor metabolisers during quinidine treatment.
摘要
对8例患者在每日服用600 - 800毫克奎尼丁治疗1周前后立即进行了司巴丁试验。治疗前，1例患者被归类为代谢缓慢者（代谢率：大于或等于20），7例患者为代谢正常者。在奎尼丁治疗期间，司巴丁代谢物（2 - 和5 - 脱氢司巴丁）的形成几乎完全被抑制。最初被归类为代谢正常者的患者在奎尼丁治疗期间表现出代谢缓慢者的表型。
相似文献
1
Sparteine oxidation is practically abolished in quinidine-treated patients.在接受奎尼丁治疗的患者中，鹰爪豆碱氧化实际上被消除了。
Br J Clin Pharmacol. 1986 Aug;22(2):194-7. doi: 10.1111/j.1365-2125.1986.tb05250.x.
2
A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.奎尼丁对人体中司巴丁氧化体内抑制作用的剂量效应研究。
Br J Clin Pharmacol. 1990 Mar;29(3):299-304. doi: 10.1111/j.1365-2125.1990.tb03639.x.
3
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.
Eur J Clin Pharmacol. 1986;31(1):69-72. doi: 10.1007/BF00870989.
4
Substantial rise in sparteine metabolic ratio during haloperidol treatment.在氟哌啶醇治疗期间，鹰爪豆碱代谢率大幅上升。
Br J Clin Pharmacol. 1989 Feb;27(2):272-5. doi: 10.1111/j.1365-2125.1989.tb05362.x.
5
Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.单次口服奎尼丁后人体动力学与司巴丁氧化多态性的关系。
Br J Clin Pharmacol. 1990 Feb;29(2):248-53. doi: 10.1111/j.1365-2125.1990.tb03628.x.
6
Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
Eur J Clin Pharmacol. 1995;48(6):501-4. doi: 10.1007/BF00194341.
7
Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.奎尼丁对硝苯地平、司巴丁和美芬妥英在人体内处置的不同影响。
Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):520-8. doi: 10.1038/clpt.1991.177.
8
Sparteine oxidation polymorphism in Denmark.丹麦的鹰爪豆碱氧化多态性
Acta Pharmacol Toxicol (Copenh). 1985 Nov;57(5):357-60. doi: 10.1111/j.1600-0773.1985.tb00058.x.
9
Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers.
Clin Pharmacol Ther. 1987 Mar;41(3):320-5. doi: 10.1038/clpt.1987.34.
10
Sparteine oxidation polymorphism in Greenlanders living in Denmark.生活在丹麦的格陵兰人的鹰爪豆碱氧化多态性
Br J Clin Pharmacol. 1986 Oct;22(4):415-9. doi: 10.1111/j.1365-2125.1986.tb02911.x.
引用本文的文献
1
Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.氢溴酸右美沙芬糖浆制剂在儿童和青少年中的药代动力学特征。
Clin Drug Investig. 2014 Sep;34(9):609-16. doi: 10.1007/s40261-014-0210-5.
2
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.抗心绞痛药物哌克昔林对CYP2D6催化代谢的临床抑制作用。
Br J Clin Pharmacol. 2004 Apr;57(4):456-63. doi: 10.1046/j.1365-2125.2003.02033.x.
3
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.接受美沙酮维持治疗患者的细胞色素P450 2D6基因型与表型之间的不一致性。
Br J Clin Pharmacol. 2003 Aug;56(2):220-4. doi: 10.1046/j.1365-2125.2003.01851.x.
4
Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.基于生理学的代谢抑制建模以及药物和代谢物相对效力评估：使用奎尼丁抑制作用研究右美沙芬与右啡烷
Br J Clin Pharmacol. 2003 Jul;56(1):57-67. doi: 10.1046/j.1365-2125.2003.01853.x.
5
Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.在具有三个或更多功能性CYP2D6基因的受试者中，奎尼丁对异喹胍羟基化的抑制作用。
Br J Clin Pharmacol. 2000 Feb;49(2):180-4. doi: 10.1046/j.1365-2125.2000.00120.x.
6
The antitussive effect of dextromethorphan in relation to CYP2D6 activity.右美沙芬的镇咳作用与细胞色素P450 2D6（CYP2D6）活性的关系。
Br J Clin Pharmacol. 1999 Sep;48(3):382-7. doi: 10.1046/j.1365-2125.1999.00029.x.
7
The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers.二氢可待因及其代谢产物二氢吗啡的内脏和躯体抗伤害感受作用。一项针对广泛代谢者和奎尼丁诱导的慢代谢者的交叉研究。
Br J Clin Pharmacol. 1998 Jun;45(6):575-81. doi: 10.1046/j.1365-2125.1998.00727.x.
8
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.利用体外和体内数据评估代谢性药代动力学相互作用的可能性。
Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004.
9
Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake.可待因摄入后奎尼丁对可待因和吗啡血浆及脑脊液浓度的影响。
Eur J Clin Pharmacol. 1996;49(6):503-9. doi: 10.1007/BF00195938.
10
Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
Eur J Clin Pharmacol. 1995;48(6):501-4. doi: 10.1007/BF00194341.
本文引用的文献
1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
Oxidation phenotype--a major determinant of metoprolol metabolism and response.氧化表型——美托洛尔代谢及反应的主要决定因素。
N Engl J Med. 1982 Dec 16;307(25):1558-60. doi: 10.1056/NEJM198212163072505.
3
Sparteine metabolism in Canadian Caucasians.
Clin Pharmacol Ther. 1982 Jan;31(1):23-9. doi: 10.1038/clpt.1982.4.
4
Clinical pharmacokinetics of quinidine.奎尼丁的临床药代动力学。
Clin Pharmacokinet. 1980 Mar-Apr;5(2):150-68. doi: 10.2165/00003088-198005020-00003.
5
Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs.三环类抗抑郁药及其他药物对人肝脏中鹰爪豆碱氧化的抑制作用。
Life Sci. 1983 Feb 14;32(7):795-800. doi: 10.1016/0024-3205(83)90315-6.
6
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.异喹胍氧化表型与普萘洛尔的药代动力学和药效学之间的关系。
Br J Clin Pharmacol. 1984 Jun;17(6):679-85. doi: 10.1111/j.1365-2125.1984.tb02403.x.
7
Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade.
Clin Pharmacol Ther. 1984 Jul;36(1):51-6. doi: 10.1038/clpt.1984.138.
8
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.高加索人中美芬妥英羟化缺乏症：一种新的氧化药物代谢多态性的频率
Clin Pharmacol Ther. 1984 Dec;36(6):773-80. doi: 10.1038/clpt.1984.256.
9
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.美芬妥英的药物遗传学：人类一种新的药物羟基化多态性
Eur J Clin Pharmacol. 1984;26(6):753-9. doi: 10.1007/BF00541938.
10
Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.人肝脏中催化异喹胍4-羟化反应的细胞色素P-450形式的底物特异性
Mol Pharmacol. 1983 Mar;23(2):474-81.
Zotero 插件